CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex (DAC) modification — a maleimidoproprionic acid (MPA) group that covalently binds to albumin in the bloodstream. This albumin binding dramatically extends the peptide's half-life to approximately 6-8 days, enabling sustained GHRH receptor stimulation from a single administration.

The peptide consists of a modified 30-amino acid GHRH(1-29) sequence with D-Ala at position 2 (for DPP-IV resistance), Gln at position 8, Ala at position 15, and Leu at position 27, plus a Lys30 residue bearing the DAC modification. These substitutions collectively enhance stability, receptor affinity, and plasma residence time compared to native GHRH.

Research with CJC-1295 has focused on its ability to produce sustained elevations in endogenous GH and IGF-1 levels while maintaining pulsatile secretion patterns. The extended half-life makes it particularly valuable for chronic dosing studies in animal models where daily injections would be impractical.

Research Applications:

• Long-acting GHRH receptor stimulation studies
• Sustained GH and IGF-1 elevation research protocols
• Protein synthesis and anabolic pathway investigations
• Lipolysis and body composition research in animal models
• Comparison of GHRH analogs with different half-lives
• Chronic dosing protocols in rodent research models

Key Specifications:

• Purity: 99.12% verified by third-party testing
• Dosage: 5mg per vial
• Category: Growth Hormone
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• 99.12% purity verified by independent third-party HPLC analysis
• Drug Affinity Complex (DAC) modification enables ~6-8 day half-life
• Sustained GH and IGF-1 elevation from single administration
• Maintains physiological pulsatile GH secretion patterns
• Molecular weight: 3,647.2 Da | CAS: 863288-34-0 | PubChem CID: 91971820